Evidence map›Paper›PMID 18613956›Full record

ArticleRetrovirology2008

Implication of TRIM alpha and TRIMCyp in interferon-induced anti-retroviral restriction activities.

Laetitia Carthagena, Mélanie C Parise, Mathieu Ringeard, Mounira K Chelbi-Alix, Uriel Hazan, Sébastien Nisole

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 66 citations in OpenAlex.

  1. Cyclophilin A Regulates Tripartite Motif 5 Alpha Restriction of HIV-1.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Viral Coinfections.Viruses · 2022
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Restriction of HIV-1 and other retroviruses by TRIM5.Nature reviews. Microbiology · 2019
    Review
  10. Review
  11. Review
  12. Virological and Immunological Outcomes of Coinfections.Clinical microbiology reviews · 2018
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Laetitia CarthagenaInstitut Cochin, Université Paris Descartes, CNRS (UMR 8104), Département des Maladies Infectieuses, 22 rue Méchain, 75014, Paris, France. laetitia.carthagena@inserm.fr
Mélanie C Parise
Mathieu Ringeard
Mounira K Chelbi-Alix
Uriel Hazan
Sébastien Nisole
Centre National de la Recherche Scientifique · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTRIM5 alpha is a restriction factor that interferes with retroviral infections in a species-specific manner in primate cells. Although TRIM5 alpha is constitutively expressed, its expression has been shown to be up-regulated by type I interferon (IFN). Among primates, a particular case exists in owl monkey cells, which express a fusion protein between TRIM5 and cyclophilin A, TRIMCyp, specifically interfering with HIV-1 infection. No studies have been conducted so far concerning the possible induction of TRIMCyp by IFN. We investigated the consequences of IFN treatment on retroviral restriction in diverse primate cells and evaluated the implication of TRIM5 alpha or TRIMCyp in IFN-induced anti-retroviral activities.

resultsFirst, we show that human type I IFN can enhance TRIM5 alpha expression in human, African green monkey and macaque cells, as well as TRIMCyp expression in owl monkey cells. In TRIM5 alpha-expressing primate cell lines, type I IFN has little or no effect on HIV-1 infection, whereas it potentiates restriction activity against N-MLV in human and African green monkey cells. In contrast, type I IFN treatment of owl monkey cells induces a great enhancement of HIV-1 restriction, as well as a strain-tropism independent restriction of MLV. We were able to demonstrate that TRIM5 alpha is the main mediator of the IFN-induced activity against N-MLV in human and African green monkey cells, whereas TRIMCyp mediates the IFN-induced HIV-1 restriction enhancement in owl monkey cells. In contrast, the type I IFN-induced anti-MLV restriction in owl monkey cells is independent of TRIMCyp expression.

conclusionTogether, our observations indicate that both TRIM5 alpha and TRIMCyp are implicated in IFN-induced anti-retroviral response in primate cells. Furthermore, we found that type I IFN also induces a TRIMCyp-independent restriction activity specific to MLV in owl monkey cells.

Indexed as

AnimalsAntiviral AgentsAntiviral Restriction FactorsAotus trivirgatusCarrier ProteinsCell LineChlorocebus aethiopsCyclophilin AGene Expression RegulationHeLa CellsHIV-1HumansInterferonsLeukemia Virus, MurineMacaca mulattaProteinsAntiviral AgentsAntiviral Restriction FactorsCarrier ProteinsCyclophilin AInterferonsProteinsRecombinant Fusion ProteinsTRIM5(alpha) protein, rhesus monkeyTRIM5 protein, humanTripartite Motif ProteinsUbiquitin-Protein Ligases

Identifiers

PMID18613956
PMCPMC2483995
OpenAlexW2157911948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.